- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

BioMed X and Daiichi Sankyo collaboration calls for research proposals

Daiichi Sankyo has launched a new collaboration with BioMed X, a German independent biomedical research institute, to explore innovative approaches in cancer treatment using multi-specific biologics, such as bi- and tri-specific antibodies.

The goal is to develop new therapies that can simultaneously engage multiple targets within the tumour microenvironment, overcoming the limitations of conventional treatments by leveraging the synergistic effects of different antitumour signalling pathways.

BioMed X and Daiichi Sankyo are inviting proposals from researchers around the world to participate in this project. Proposals should demonstrate originality and can target any solid tumour indication. The new research team will join seven other research groups at the BioMed X Institute in Germany. Project proposals are to be submitted via the BioMed X Career Space before 9 March 2025.

Christian Tidona, Founder and Managing Director of the BioMed X Institute, commented: “Partnering with Daiichi Sankyo on the MTT project allows us to expand our research in oncology, focusing on next-generation biologics that can truly make a difference for cancer patients. This collaboration exemplifies our commitment to pioneering innovative therapeutic approaches.”

- Advertisement -
Lauren Alexander
Lauren Alexander
Marketing and Content Executive | Uniphar Commercial

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription